Eravacycline (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Eravacycline" in English language version.

refsWebsite

Global rank English rank

10nih.gov

4^th place

6doi.org

2^nd place

6worldcat.org

5^th place

4web.archive.org

1^st place

4tphase.com

low place

2semanticscholar.org

11^th place

8^th place

2healio.com

low place

2clinicaltrials.gov

5,225^th place

4,062^nd place

1europa.eu

68^th place

117^th place

1businesswire.com

615^th place

407^th place

1drugs.com

399^th place

333^rd place

1rero.ch

3,510^th place

2,263^rd place

businesswire.com

"FDA Grants QIDP Designation to Eravacycline, Tetraphase's Lead Antibiotic Product Candidate | Business Wire". businesswire.com. 15 July 2013. Retrieved 20 November 2016.

clinicaltrials.gov

"Efficacy and Safety Study of Eravacycline Compared With Meropenem in Complicated Intra-abdominal Infections - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 27 July 2017.
"Efficacy and Safety Study of Eravacycline Compared With Ertapenem in Participants With Complicated Urinary Tract Infections - Full Text View - ClinicalTrials.gov". clinicaltrials.gov. Retrieved 27 July 2017.

doi.org

Solomkin J, Evans D, Slepavicius A, Lee P, Marsh A, Tsai L, et al. (16 November 2016). "Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial". JAMA Surgery. 152 (3): 224–232. doi:10.1001/jamasurg.2016.4237. ISSN 2168-6262. PMID 27851857. S2CID 42977246.
Zhanel GG, Cheung D, Adam H, Zelenitsky S, Golden A, Schweizer F, et al. (1 April 2016). "Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent". Drugs. 76 (5): 567–588. doi:10.1007/s40265-016-0545-8. ISSN 1179-1950. PMID 26863149. S2CID 36285428.
Sutcliffe JA, O'Brien W, Fyfe C, Grossman TH (1 November 2013). "Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens". Antimicrobial Agents and Chemotherapy. 57 (11): 5548–5558. doi:10.1128/AAC.01288-13. ISSN 1098-6596. PMC 3811277. PMID 23979750.
Solomkin JS, Ramesh MK, Cesnauskas G, Novikovs N, Stefanova P, Sutcliffe JA, et al. (1 January 2014). "Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections". Antimicrobial Agents and Chemotherapy. 58 (4): 1847–1854. doi:10.1128/AAC.01614-13. ISSN 1098-6596. PMC 4023720. PMID 24342651.
Abdallah M, Olafisoye O, Cortes C, Urban C, Landman D, Quale J (1 March 2015). "Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City". Antimicrobial Agents and Chemotherapy. 59 (3): 1802–1805. doi:10.1128/AAC.04809-14. ISSN 1098-6596. PMC 4325809. PMID 25534744.
Fyfe C, LeBlanc G, Close B, Nordmann P, Dumas J, Grossman TH (22 August 2016). "Eravacycline is active against bacterial isolates expressing the polymyxin resistance gene mcr-1" (PDF). Antimicrobial Agents and Chemotherapy. 60 (11): 6989–6990. doi:10.1128/AAC.01646-16. ISSN 0066-4804. PMC 5075126. PMID 27550359.

drugs.com

"Eravacycline Dosage Guide + Max Dose, Adjustments". Drugs.com. Retrieved 15 May 2025.

europa.eu

ema.europa.eu

"Xerava EPAR". European Medicines Agency. 8 October 2018. Retrieved 29 June 2024.

healio.com

"Phase 3 IGNITE4 trial to examine safety, efficacy of IV eravacycline in cIAIs". Healio. 19 October 2016. Retrieved 16 January 2023.
"IGNITE2: Eravacycline inferior to levofloxacin, but IV formulation shows promise". Healio. 8 July 2016. Retrieved 16 January 2023.

nih.gov

pubmed.ncbi.nlm.nih.gov

Solomkin J, Evans D, Slepavicius A, Lee P, Marsh A, Tsai L, et al. (16 November 2016). "Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial". JAMA Surgery. 152 (3): 224–232. doi:10.1001/jamasurg.2016.4237. ISSN 2168-6262. PMID 27851857. S2CID 42977246.
Zhanel GG, Cheung D, Adam H, Zelenitsky S, Golden A, Schweizer F, et al. (1 April 2016). "Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent". Drugs. 76 (5): 567–588. doi:10.1007/s40265-016-0545-8. ISSN 1179-1950. PMID 26863149. S2CID 36285428.
Sutcliffe JA, O'Brien W, Fyfe C, Grossman TH (1 November 2013). "Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens". Antimicrobial Agents and Chemotherapy. 57 (11): 5548–5558. doi:10.1128/AAC.01288-13. ISSN 1098-6596. PMC 3811277. PMID 23979750.
Solomkin JS, Ramesh MK, Cesnauskas G, Novikovs N, Stefanova P, Sutcliffe JA, et al. (1 January 2014). "Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections". Antimicrobial Agents and Chemotherapy. 58 (4): 1847–1854. doi:10.1128/AAC.01614-13. ISSN 1098-6596. PMC 4023720. PMID 24342651.
Abdallah M, Olafisoye O, Cortes C, Urban C, Landman D, Quale J (1 March 2015). "Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City". Antimicrobial Agents and Chemotherapy. 59 (3): 1802–1805. doi:10.1128/AAC.04809-14. ISSN 1098-6596. PMC 4325809. PMID 25534744.
Fyfe C, LeBlanc G, Close B, Nordmann P, Dumas J, Grossman TH (22 August 2016). "Eravacycline is active against bacterial isolates expressing the polymyxin resistance gene mcr-1" (PDF). Antimicrobial Agents and Chemotherapy. 60 (11): 6989–6990. doi:10.1128/AAC.01646-16. ISSN 0066-4804. PMC 5075126. PMID 27550359.

ncbi.nlm.nih.gov

Sutcliffe JA, O'Brien W, Fyfe C, Grossman TH (1 November 2013). "Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens". Antimicrobial Agents and Chemotherapy. 57 (11): 5548–5558. doi:10.1128/AAC.01288-13. ISSN 1098-6596. PMC 3811277. PMID 23979750.
Solomkin JS, Ramesh MK, Cesnauskas G, Novikovs N, Stefanova P, Sutcliffe JA, et al. (1 January 2014). "Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections". Antimicrobial Agents and Chemotherapy. 58 (4): 1847–1854. doi:10.1128/AAC.01614-13. ISSN 1098-6596. PMC 4023720. PMID 24342651.
Abdallah M, Olafisoye O, Cortes C, Urban C, Landman D, Quale J (1 March 2015). "Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City". Antimicrobial Agents and Chemotherapy. 59 (3): 1802–1805. doi:10.1128/AAC.04809-14. ISSN 1098-6596. PMC 4325809. PMID 25534744.
Fyfe C, LeBlanc G, Close B, Nordmann P, Dumas J, Grossman TH (22 August 2016). "Eravacycline is active against bacterial isolates expressing the polymyxin resistance gene mcr-1" (PDF). Antimicrobial Agents and Chemotherapy. 60 (11): 6989–6990. doi:10.1128/AAC.01646-16. ISSN 0066-4804. PMC 5075126. PMID 27550359.

rero.ch

doc.rero.ch

Fyfe C, LeBlanc G, Close B, Nordmann P, Dumas J, Grossman TH (22 August 2016). "Eravacycline is active against bacterial isolates expressing the polymyxin resistance gene mcr-1" (PDF). Antimicrobial Agents and Chemotherapy. 60 (11): 6989–6990. doi:10.1128/AAC.01646-16. ISSN 0066-4804. PMC 5075126. PMID 27550359.

semanticscholar.org

api.semanticscholar.org

Solomkin J, Evans D, Slepavicius A, Lee P, Marsh A, Tsai L, et al. (16 November 2016). "Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial". JAMA Surgery. 152 (3): 224–232. doi:10.1001/jamasurg.2016.4237. ISSN 2168-6262. PMID 27851857. S2CID 42977246.
Zhanel GG, Cheung D, Adam H, Zelenitsky S, Golden A, Schweizer F, et al. (1 April 2016). "Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent". Drugs. 76 (5): 567–588. doi:10.1007/s40265-016-0545-8. ISSN 1179-1950. PMID 26863149. S2CID 36285428.

tphase.com

ir.tphase.com

"Tetraphase Announces Top-Line Results From IGNITE2 Phase 3 Clinical Trial of Eravacycline in cUTI (NASDAQ:TTPH)". ir.tphase.com. Archived from the original on 21 November 2016. Retrieved 20 November 2016.
"Tetraphase Pharmaceuticals Provides Update on Eravacycline Regulatory and Development Status (NASDAQ:TTPH)". ir.tphase.com. Archived from the original on 21 November 2016. Retrieved 20 November 2016.
"Tetraphase Announces Positive Top-Line Results from Phase 3 IGNITE4 Clinical Trial in Complicated Intra-Abdominal Infections (NASDAQ:TTPH)". ir.tphase.com. Archived from the original on 1 August 2017. Retrieved 27 July 2017.
"Tetraphase Pharmaceuticals Doses First Patient in IGNITE3 Phase 3 Clinical Trial of Once-daily IV Eravacycline in cUTI (NASDAQ:TTPH)". ir.tphase.com. Archived from the original on 7 August 2017. Retrieved 27 July 2017.

web.archive.org

"Tetraphase Announces Top-Line Results From IGNITE2 Phase 3 Clinical Trial of Eravacycline in cUTI (NASDAQ:TTPH)". ir.tphase.com. Archived from the original on 21 November 2016. Retrieved 20 November 2016.
"Tetraphase Pharmaceuticals Provides Update on Eravacycline Regulatory and Development Status (NASDAQ:TTPH)". ir.tphase.com. Archived from the original on 21 November 2016. Retrieved 20 November 2016.
"Tetraphase Announces Positive Top-Line Results from Phase 3 IGNITE4 Clinical Trial in Complicated Intra-Abdominal Infections (NASDAQ:TTPH)". ir.tphase.com. Archived from the original on 1 August 2017. Retrieved 27 July 2017.
"Tetraphase Pharmaceuticals Doses First Patient in IGNITE3 Phase 3 Clinical Trial of Once-daily IV Eravacycline in cUTI (NASDAQ:TTPH)". ir.tphase.com. Archived from the original on 7 August 2017. Retrieved 27 July 2017.

worldcat.org

search.worldcat.org

Solomkin J, Evans D, Slepavicius A, Lee P, Marsh A, Tsai L, et al. (16 November 2016). "Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial". JAMA Surgery. 152 (3): 224–232. doi:10.1001/jamasurg.2016.4237. ISSN 2168-6262. PMID 27851857. S2CID 42977246.
Zhanel GG, Cheung D, Adam H, Zelenitsky S, Golden A, Schweizer F, et al. (1 April 2016). "Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent". Drugs. 76 (5): 567–588. doi:10.1007/s40265-016-0545-8. ISSN 1179-1950. PMID 26863149. S2CID 36285428.
Sutcliffe JA, O'Brien W, Fyfe C, Grossman TH (1 November 2013). "Antibacterial activity of eravacycline (TP-434), a novel fluorocycline, against hospital and community pathogens". Antimicrobial Agents and Chemotherapy. 57 (11): 5548–5558. doi:10.1128/AAC.01288-13. ISSN 1098-6596. PMC 3811277. PMID 23979750.
Solomkin JS, Ramesh MK, Cesnauskas G, Novikovs N, Stefanova P, Sutcliffe JA, et al. (1 January 2014). "Phase 2, randomized, double-blind study of the efficacy and safety of two dose regimens of eravacycline versus ertapenem for adult community-acquired complicated intra-abdominal infections". Antimicrobial Agents and Chemotherapy. 58 (4): 1847–1854. doi:10.1128/AAC.01614-13. ISSN 1098-6596. PMC 4023720. PMID 24342651.
Abdallah M, Olafisoye O, Cortes C, Urban C, Landman D, Quale J (1 March 2015). "Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City". Antimicrobial Agents and Chemotherapy. 59 (3): 1802–1805. doi:10.1128/AAC.04809-14. ISSN 1098-6596. PMC 4325809. PMID 25534744.
Fyfe C, LeBlanc G, Close B, Nordmann P, Dumas J, Grossman TH (22 August 2016). "Eravacycline is active against bacterial isolates expressing the polymyxin resistance gene mcr-1" (PDF). Antimicrobial Agents and Chemotherapy. 60 (11): 6989–6990. doi:10.1128/AAC.01646-16. ISSN 0066-4804. PMC 5075126. PMID 27550359.